Close Menu

NEW YORK (GenomeWeb) – With an exclusive license for pomaglumetad methionil — a late-stage schizophrenia drug that Eli Lilly stopped developing due to poor efficacy in 2012 — San Diego-based Denovo Biopharma said it would apply proprietary testing methods to screen for genetic biomarkers and try to home in on which patients are likely to respond to the therapy.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Politico reports President Donald Trump has signed the $2 trillion coronavirus relief package.

NPR reports that graduate students in the US are helping with SARS-CoV-2 testing.

A new analysis finds that peer review improves the quality of preprints just a little bit, according to ScienceInsider.

In PLOS this week: epigenetic drug triggers anti-viral activity, viral diversity among individuals with HIV experiencing virological failure, and more.